GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (FRA:7UM) » Definitions » Capital Expenditure

Ultimovacs ASA (FRA:7UM) Capital Expenditure : €-0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Ultimovacs ASA's cash flow for capital expenditures for the three months ended in Mar. 2024 was €-0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.00 Mil.

Ultimovacs ASA Capital Expenditure Historical Data

The historical data trend for Ultimovacs ASA's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Capital Expenditure Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -0.02 -0.50 -0.01 -0.02 -

Ultimovacs ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ultimovacs ASA Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultimovacs ASA (FRA:7UM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (FRA:7UM) » Definitions » Capital Expenditure
Comparable Companies
OSL:NYKD OSL:AZT OSL:HBC OSL:BGBIO OSL:CIRCA OSL:EXTX OSL:TRMED OSL:LYTIX OSL:ABS OSL:PCIB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ULTIo:Sweden ULTI:Norway 7UM:Germany
Address
Ullernchausseen 64, Oslo, NOR, 0379
Website
https://www.ultimovacs.com
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (FRA:7UM) Headlines

No Headlines